In vivo T-cell depletion with anti-thymocyte globulin (ATG) can attenuate GvHD but may increase infection and relapse risks. ATG-Fresenius (ATG-F) at a dose of 60 mg/kg was standard GvHD prophylaxis in unrelated donor hematopoietic stem cell transplantation (HSCT) at our institution. We changed to an incremental reduced dose regimen of 35 mg/kg and extended ATG prophylaxis to include older matched-related donor transplants considered to be at higher risk of GvHD. A total of 265 adults with hematological malignancies receiving a first allogeneic HSCT after myeloablative conditioning between 2009 and 2014 were analyzed in this cohort study. Patients had either received higher dose (n = 32) or lower dose ATG-F (n = 88) or no ATG (n = 145). ATG-F was associated with slower engraftment and less chronic GvHD, whereas no effect was noted on acute grade II-IV GvHD and relapse incidence. Transplant-related mortality (TRM) was lower and survival higher with lower dose, but not with higher dose ATG-F. Both ATG-F groups were associated with more viral reactivation, viral disease and bacterial blood stream infection, but not invasive fungal infection, and with slower immune reconstitution. The recently adopted strategy of using lower doses of ATG-F in unrelated and older age-related donor HSCT appears to reduce TRM without increasing disease relapse, leading to slightly enhanced survival.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is standard treatment for many types of hematologic malignancies and other diseases. 1, 2 Results have improved over the years. 3 Major risks of allogeneic HSCT include GvHD, incomplete immune reconstitution and relapse. GvL effects, as well as GvHD are mediated mainly by donor T lymphocytes. To prevent GvHD, T-cell depletion has been used for many years in allogeneic HSCT. 4 However, the optimal use of T-cell depleting agents has never been defined. Large clinical trials are rare and the best balance between T-cells contributing to GvL and immune reconstitution vs reducing GvHD risks has not been defined. Although in vitro T-cell depletion effectively abrogates GvHD, it is associated with higher relapse rates and slow and incomplete immune reconstitution. 5, 6 In vivo T-cell depletion is based on drugs such as polyclonal anti-thymocyte globulins (ATG), the monoclonal anti-CD52 alemtuzumab and other antibodies. ATG has been shown in randomized clinical trials to decrease mainly chronic GvHD (cGvHD) but not to prolong survival. [7] [8] [9] [10] [11] [12] [13] However, studies were possibly underpowered and without sufficient follow-up to detect survival differences. ATG-Fresenius (ATG-F) at a dose of 60 mg/kg (20 mg/kg on days − 3, − 2 and − 1) was studied in one of the largest randomized trials with ATG 7 and became therefore standard GvHD prophylaxis in unrelated donor HSCT at our institution. Because of the infusion-related reactions to the first dose of ATG and concerns about infectious complications, we changed the dosing to an incremental dose regimen (5, 10 and 20 mg/kg on days − 3, − 2 and − 1, respectively) and a reduced total dose of 35 mg/kg in 2012. In addition, we started using the same ATG regimen in matched-related donor HSCT with increased risk of GvHD (donor and/or recipient age440 years).
14 This report evaluates this strategy.
PATIENTS AND METHODS
A total of 265 adult patients with hematological malignancies, recipients of myeloablative or reduced intensity conditioning and allogeneic HSCT between January 2009 and July 2014 were analyzed in this retrospective single-center cohort study. Two cohorts (ATG-F higher dose, with 60 mg/kg ATG-F (n = 32) and ATG-F lower dose with 35 mg/kg ATG-F (n = 88)) and a control group without ATG (n = 145) were analyzed. Patient characteristics are shown in Table 1 . In all, 248 patients received peripheral blood grafts (93.6%) and 17 patients bone marrow grafts (6.4%) from unrelated donors (n = 148, 55.8%) or HLA-identical relatives (n = 117, 44.2%). In total, 386 patients underwent allogeneic HSCT during the study period. Reasons for excluding 121 patients were: receiving cord blood (7), haplo-identical (3) or syngeneic grafts (4), non-myeloablative conditioning (61) or second transplants (28), as well as patients o16 years (9) and those transplanted for non-malignant diseases (9). Patients did not receive post-transplant GCSF.
All patients provided informed consent, the study was approved by the local ethics committee.
From 2009 to 2012 ATG-F was added in a dose of 60 mg/kg (20 mg/kg on days − 3, − 2 and − 1) in patients undergoing unrelated donor transplantation, from 2012 to July 2014 ATG-F was applied in a reduced dose of 35 mg/kg incrementally (5, 10 and 20 mg/kg on days − 3, − 2 and − 1, respectively) in order to reduce the first-dose toxicity to recipients of unrelated donor HSCT or HLA-identical relatives with donor or recipient age440 years considered to be at higher risks of GvHD. Patients had either received higher dose (n = 32) or lower dose ATG-F (n = 88) or no ATG (n = 145).
Diseases included AML (n = 80), ALL (n = 50), CML (n = 11), myelodysplastic syndrome or myelofibrosis (n = 65) and lymphoid neoplasia (n = 59). The conditioning regimens were either Cyclophosphamide and Busulfan (Cyclophosphamide at a dose of 120 mg/kg and IV Busulfan at a dose of 12.8 mg/kg, CyBu, n = 113), Cyclophosphamide and TBI (12 Gy; CyTBI, n = 66), Cytarabine, Carmustine, Etoposide and Melphalan (BEAM, n = 47) or Fludarabine (150 mg/m 2 ) with IV Busulfan (6.4 mg/kg) or Melphalan (140 mg/m 2 ; FluBu/FluMel, n = 39). Groups differed by some variables. There were more patients with myelodysplastic syndrome or myelofibrosis in the higher dose ATG-F group, more AML in the lower dose ATG-F group and more lymphoid neoplasms in the control group, differences were of borderline significance only (P = 0.04). As a consequence, there were differences among conditioning regimens (more BEAM in the control group, being used for lymphoma, and more FluBu/FluMel in the ATG-F groups). By design there were more unrelated donors and correspondingly younger donor age in both ATG-F groups. Donor-recipient CMV serostatus and blood group match differed in the three groups as shown in Table 1 . Patients in the three groups did not differ by age, disease stage and donor-recipient gender matching. Median follow-up of surviving patients was 1239 days in the control group, 369 days in the lower dose ATG-F group and 1104 days in the higher dose ATG-F group.
Outcomes analyzed were: time to neutrophil engraftment (defined as the first of 3 consecutive days of an absolute neutrophil count exceeding 0.5 × 109/L), incidence of acute GvHD (aGvHD) and cGvHD, disease relapse, Abbreviations: ATG-F = anti-thymocyte-globulin Fresenius; BEAM = cytarabine-carmustine-etoposide-melphalan; CI = confidence interval; CyBu = cyclophosphamide-busulfan; CyTBI = cyclophosphamide+TBI, FluBu = fludarabine-busulfan; FluMel = fludarabine-melphalan; MDS = myelodysplastic syndrome, MPN = myeloproliferative syndrome.
Lower dose ATG results in improved survival L Binkert et al transplant-related mortality (TRM), relapse-free survival (RFS), GvHD-free/ RFS (GRFS, according to Holtan et al.
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) and overall survival at 2 years after HSCT. In addition immune reconstitution measured with Ig levels, CD4 and absolute lymphocyte count at day 100 and infectious complications, namely bacterial blood stream infections (BSI), viral reactivations and diseases (defined as CMV or EBV disease, respiratory virus infection, BK virus-associated cystitis, herpes or hepatitis viremia) and invasive fungal infections (defined as fungemia or pulmonary aspergillosis) within the first 6 months from transplantation were assessed. In addition, hepatic and renal ATG toxicity was evaluated with bilirubin and creatinine levels at day − 5 to +5 from HSCT.
Groups were compared using the χ 2 test for categorical and the Kruskall-Wallis test for continuous variables. The Kaplan-Meier estimator and the cumulative incidence function were used where appropriate. 16 For cumulative incidence of relapse, TRM was used as competing risk, for GvHD incidence death due to other causes was competing risk. Multivariate analysis of survival was evaluated using Cox proportional hazards regression. 17 All P-valueso 0.05 were considered significant. Statistical analyses were performed with SPSS 22 (SPSS/IBM, Armonk, NY, USA) and NCSS 10 (Statistical Software (2015) NCSS, LLC. Kaysville, UY, USA, ncss.com/software/ncss).
RESULTS
Comparisons of univariate outcomes in the three groups are shown in Table 2 .
Engraftment was delayed by ATG-F at both dose levels, time to neutrophil engraftment was longer by 4 days in the ATG-F lower dose and by 3 days in the ATG-F higher dose group compared with controls (P o0.001).
No ATG effect was noted on grade II-IV aGvHD. Cumulative incidence of cGvHD was significantly lower in both ATG-F groups compared with the control group (P = 0.03, Figure 1 ). The differences between the groups were larger at 1 year than at 2 years. One and two year incidences were 34 and 51% in the lower dose vs 47 and 58% in the higher dose ATG-F group vs 66 and 70% in the control group.
Relapse did not differ among groups but TRM was lower with lower dose ATG-F (8% vs 28% in the higher dose vs 18% in the control group, P = 0.05, Figure 2 ).
RFS and GRFS were highest in the lower dose ATG-F group although this did not reach statistical significance. RFS was 65% in the lower dose ATG-F group vs 49% in the control group and 38% in the higher dose ATG-F group. GRFS was 54% with lower dose ATG-F, compared with 42% in the control group and 31% in the higher dose ATG-F group. Abbreviations: ATG-F = anti-thymocyte-globulin Fresenius; BSI = blood stream infection; CI = confidence interval; GRFS = GvHD-free/RFS; RFS = relapse-free survival. Two year overall survival was highest in the lower dose ATG-F group (75% vs 50% in the higher dose vs 60% in the control group, P = 0.04, Figure 3 ) and differences remained after adjustment for significant confounders in the multivariate model (Table 3) where lower dose ATG-F was associated with lower risk of death (RR 0.44 (0.24-0.81), P = 0.02), after adjustment for disease stage, patient age and donor type compared with controls. Disease stage was the variable most significantly associated with risk of death (early stage RR 1.0, intermediate stage RR 1.5 (0.87-2.68), advanced stage RR 3.3 (1.96-5.6), P o0.001). Donor type was not significantly associated with risk of death (RR 1.5 (0.92-2.55), P = 0.1, for unrelated donors compared with matched-related donors). This variable was included in the model in order to test for interactions with ATG-F of which there were none. Other variables, such as conditioning, disease type, donor-recipient CMV serostatus-, gender-and blood group matching and stem cell source were not significant.
No difference was found in absolute lymphocyte count and Ig levels at day 100, but CD4+ cell count at day 100 was significantly lower in both ATG-F groups (0.09 × 10 9 /L in the lower dose vs 0.06 × 10 9 /L in the higher dose vs 0.2 × 10 9 /L in the control group, Po 0.001). The percentage of patients achieving full donor chimerism in whole blood at day 100 did not differ among groups, however, we did not look at the chimerism of the CD3+ cells.
ATG-F was associated with some toxicity. Significantly higher maximum bilirubin levels assessed on days − 5 to day +5 were found in both ATG-F groups (25 μmol/L in the lower dose vs 36 μmol/L in the higher dose vs 13 μmol/L in the control group). Maximum creatinine levels at day − 5 to day +5 were significantly higher in the higher dose ATG-F group (80 μmol/L) compared with the control (73 μmol/L) and lower dose ATG-F group (68 μmol/L, P o 0.05). Fever and rigors were common with ATG-F, but these side effects were not quantified.
ATG-F was associated with more infections, in particular viral reactivations, viral diseases and bacterial BSI, but not invasive fungal infections as shown in Table 2 . EBV but not CMV reactivation was significantly increased in both ATG-F groups (51% in the lower dose vs 66% in the higher dose vs 5% in the control group, P o 0.001, respectively, 35% in the lower dose vs 36% in the higher dose vs 18% in the control group, P = 0.13; Figure 4 ). The incidence of viral infections was significantly increased in the groups with ATG-F (20% in the controls vs 29% in the lower dose vs 49% in the higher dose ATG-F group, P o 0.001, Figure 5 ). The incidence of bacterial BSI was slightly higher with ATG-F (12% in the controls vs 21% in the lower dose vs 27% in the higher dose ATG-F group, P = 0.46) whereas no differences in invasive fungal infections were noted. However, the overall number of fungal infections was low in our series. Figure 3 . Survival of patients in the higher dose, lower dose ATG-F and control group, respectively. Survival was significantly higher in the lower dose ATG-F group compared with the control and higher dose ATG-F group (P = 0.04). Abbreviations: ATG-F = anti-thymocyte-globulin Fresenius; CI = confidence interval; RR = relative risk. 
DISCUSSION
We evaluated here the strategies to reduce GvHD risks in allogeneic HSCT by using ATG-F at two different dose levels and in different patient populations. Our main finding was that lower dose ATG-F prolonged survival, decreased TRM and reduced the incidence of cGvHD especially in the first year after transplantation, but did not affect incidence of aGvHD. In contrast, higher dose ATG-F did not induce better survival or lower TRM, suggesting a dose-dependent effect. Relapse rates were similar in all groups. Some dose-dependent liver and renal toxicities were found following ATG-F. Engraftment was delayed and immune reconstitution as assessed by CD4+ cell counts at day 100 was lower with ATG-F at both dose levels. Consistently, the incidence of infection was higher in the ATG-F groups. Especially EBV but also CMV reactivation incidence was higher in the ATG-F groups, viral infections were more common and bacterial BSI appeared to be more frequent. No difference was found in invasive fungal infections. From our data we cannot decide if this is based on different biologic effects or mainly due to the low number of fungal infections in all three groups.
Our interpretation is that ATG-F may reduce some of the complications of allogeneic HSCT by diminishing risks of cGvHD, and thereby lead to improved results particularly when the lower dose is used. This possible benefit comes at the cost of poorer immune reconstitution, more infectious risks and some direct toxicity.
Groups differed by some variables, as disease types, donors and conditioning regimens were not equally distributed among groups. However, careful adjustment for covariates did not change the main results of this analysis. Although unrelated donor transplants had a somewhat poorer survival, donor type was not significant in our multivariate model, demonstrating that differences in outcome between unrelated and related donors were successfully reduced in recent years. No interactions were noted between lower dose ATG-F and type of donor, indicating that ATG-F effects were independent of donor type. Several studies confirm these data, showing similar outcomes regardless of donor type. [18] [19] [20] We found a survival benefit with lower dose ATG-F. Previous studies, of which some are published as abstracts only, found some advantage for ATG treatment. However, with the exception of one study with matched-related HSCT only, 21 these studies did not reach statistical significance. [7] [8] [9] [10] 13, 22 The survival benefit shown here may be due to an improved selection of patients receiving ATG. Although the imbalance of known risk factors was adjusted for by statistical analysis, larger series of patients need to be analyzed for confirmation.
Four randomized studies showed a significant decrease in acute and cGvHD after in vivo T-cell depletion with ATG. 7, 10, 12, 13 In our study, we found that lower dose ATG-F decreased the incidence of cGvHD without influencing aGvHD. Similar results have been reported by Bonifazi et al.
23 Figure 3 shows a lower incidence of cGvHD, mainly in the first year post transplant in the lower dose ATG-F group. Although only few patients contribute to the slight increase in the second year, it is possible that lower dose ATG-F only delays rather than eliminates cGvHD.
Engraftment was significantly slower in both ATG-F groups, possibly related to inflammation and cytokine storm. This effect had already been reported in previous studies. 5, 7, 9, 10, 22, 23 Incidence of CMV and EBV reactivations, as well as symptomatic viral infections and bacterial BSI, but not invasive fungal infections were increased especially when using higher dose ATG. This can be attributed to the immunosuppressive effect of ATG. This coincides with slower immune reconstitution with CD4+ cell counts being lower in both ATG groups at day 100. Other groups had similar findings, for example, Bacigalupo et al., 10 who found more lethal infections with ATG, but others did not find any difference in infection-related mortality. 7, 13, 22 Previous studies had only analyzed fatal infections or patients with 41 any infectious episode without further differentiation. We analyzed infections as viral reactivation, symptomatic viral infection, bacterial and fungal infection within 6 months from transplantation. It appears that ATG-F use does have a dose-dependent negative impact on viral infections.
We found some hepatic and renal toxicity of ATG-F, bilirubin and creatinine levels from day − 5 to day +5 being significantly higher, especially in the higher dose ATG group, and might be related to cytokine release and activation of the coagulation system. Not many studies have analyzed toxic effects of ATG, but similar findings have been reported earlier. 24, 25 Our study has several limitations: The study is retrospective, controls are in part historical, although the study period is reasonably short (2009) (2010) (2011) (2012) (2013) (2014) . The lower dose ATG group had a shorter follow-up period than the other two groups, because ATG-F was only given in the lower dose in the later study period (Table 2) . Groups differed by some baseline variables, as shown in Table 1 , however, we carefully adjusted for these differences in the multivariate analysis. Finally, we cannot exclude that the lower dose ATG group showing better outcome included more low-risk patients in ways not measured by our analysis. However, the fact that lower dose ATG was given to patients with unrelated donors and to patients with related donors if they were older, lends credibility to our hypothesis as these patients are considered to be at higher risks of GvHD and other complications.
In summary, our results are consistent with previous studies, including randomized trials and observational studies, showing in the majority that ATG as part of the conditioning reduces GvHD, particularly cGvHD without increasing relapse but without a survival benefit, as reviewed by Storek et al. 26 In our cohort though, there is a survival benefit in patients with unrelated donor HSCT and with related donor HSCT at high risk of GvHD receiving lower dose ATG-F with less TRM in spite of higher risks of infectious complications.
In randomized trials, higher doses of ATG have been used for unrelated donor HSCT and lower doses for related transplantation. 7, 10, 12, 13, 23 It is possible that using lower doses for unrelated donor HSCT and related donor HSCT at higher risks of GvHD proves to be the best treatment option.
The recently adopted strategy of using lower doses of ATG-F in unrelated and older age-related donor HSCT appears to be associated with lower TRM and lower mortality in this rather heterogenous patient population. Results therefore require confirmation by other studies. 
